Skip to main content
TipRanks
Go Ultimate75% OFF

Jupiter Life Line Hospitals Ltd. (JLHL) AI Stock Analysis

0 Followers
IN:JLHL

Jupiter Life Line Hospitals Ltd.

(NSE:JLHL)

Select Model
Rating:66Neutral
Price Target:INR 306.00â–²(5.35% Upside)
Action:downgraded
Date:10/26/26

Solid financial performance and positive earnings call sentiment on growth initiatives are the primary drivers, tempered by weak technical momentum and stretched valuation.

Positive Factors
Revenue and Profitability GrowthConsistent revenue expansion alongside a sustained shift to positive earnings indicates that the hospital network is scaling its operating base and converting growth into profitability. This supports reinvestment, strengthens earnings resilience, and provides a durable foundation for expansion over the next several quarters.
Negative Factors
Weak Free Cash FlowNegative free cash flow means operating cash is currently being absorbed by capital spending or working capital rather than accumulating after reinvestment. If this persists, expansion may require additional debt or reduce financial flexibility, despite positive operating cash flow.

Jupiter Life Line Hospitals Ltd. (JLHL) vs. iShares MSCI India ETF (INDA)

-20%-15%-10%-5%0%5%10%15%IN:JLHL-1.06%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 96.05B
Dividend Yield
0.07%
Average Volume (3M)
42.89K
Price to Earnings (P/E)
51.0
Beta (1Y)
0.44
Revenue Growth
16.71%
EPS Growth
-6.09%
Country
India
Employees
3,002
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Jupiter Life Line Hospitals Ltd. Business Overview & Revenue Model

Company Description

Jupiter Life Line Hospitals Limited, established in Mumbai, India, in 2002, operates as a multi-specialty healthcare provider throughout the country under its Jupiter brand. The company delivers a comprehensive range of medical and surgical services...

Jupiter Life Line Hospitals Ltd. Earnings Call Summary

Earnings Call Date:Oct 23, 2026(Q2-2027)|% Change Since:19.58%|Next Earnings Date:Nov 10, 2023
Earnings Call SentimentPositive

The call was broadly constructive, supported by strong Q2 and H1 financial results, improving Dombivli EBITDA, a progressing expansion pipeline, solid mature-hospital occupancy, and a strong liquidity and leverage position. Counterbalancing factors included low Dombivli occupancy, ongoing hiring and insurance-empanelment work, Indore EBITDA fluctuations, capacity constraints at mature hospitals, and uncertainty around regulatory margin caps and formal financial guidance. Highlights significantly outweighed the lowlights.

Positive Updates

Pune South Land Acquisition Approved
The Board approved acquisition of the 11,452 sq m land leased for Pune South Hospital for INR 150 crores. The INR 50 crores deposit already paid will be adjusted, limiting incremental cash outflow to INR 100 crores. Registration was expected in the coming few days, and the Pune South project remains on schedule.

Negative Updates

Dombivli Occupancy Remains in the Mid-30s
Dombivli occupancy was currently in the mid-30s. Management said Q3 occupancies are traditionally lower than Q2 across its units, so some moderation should be expected, although the effect relative to ongoing growth remains to be seen.

Company Guidance

Management expects Pune South land to be registered in the coming few days, Mira-Bhayandar’s next phase to commence before the end of this financial year, and BKC to soon enter regulatory clearance; Dombivli’s broad budgetary model remains EBITDA breakeven in two years, with doctor hiring ongoing for the next year and a half, transplants starting in the next couple of quarters, and radiation oncology starting in the next quarter. Indore beds are not expected to be added in six months or for the next couple of quarters, with the target of reaching mid-60s occupancy first. Insurance typically takes about a year, empanelments around a year, and Dombivli fixed costs were INR 6 crore-INR 8 crore. The self-imposed debt ceiling is 3x of EBITDA; EBITDA to net cash has averaged around 70%, potentially tempered to some 60% something if net debt levels rise; maintenance CapEx is about INR 10 crores-INR 20 crores per unit, averaged over the next four or five years. For a new hospital, occupancy should go up and ARPOB rise faster than inflation over the first three years, while no financial guidance has been provided.

Jupiter Life Line Hospitals Ltd. Financial Statement Overview

Summary

Strong revenue growth and rising profitability with a robust balance sheet featuring low leverage, though negative free cash flow from expansion capex introduces some short-term risks.

Income Statement

82Very Positive

Balance Sheet

88Very Positive

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue16.21B15.00B12.62B10.70B8.93B7.33B
Gross Profit9.24B8.69B10.31B8.55B7.11B4.07B
EBITDA3.72B3.43B3.25B2.61B2.06B1.50B
Net Income1.86B1.94B1.93B1.77B729.05M511.28M
Balance Sheet
Total Assets25.60B23.83B19.05B12.81B9.86B9.09B
Cash, Cash Equivalents and Short-Term Investments4.32B5.44B6.03B3.18B1.36B1.06B
Total Debt6.69B5.84B3.93B623.41M4.69B4.95B
Total Liabilities9.30B8.39B5.49B1.13B6.22B6.20B
Stockholders Equity16.30B15.44B13.56B11.69B3.66B2.94B
Cash Flow
Free Cash Flow0-2.34B-674.22M292.26M399.24M452.40M
Operating Cash Flow02.68B2.53B1.15B1.17B1.37B
Investing Cash Flow0-4.65B-2.09B-758.89M-1.04B-852.46M
Financing Cash Flow01.60B3.01B1.28B175.00M322.02M

Jupiter Life Line Hospitals Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price290.45

Price Trends

50DMA267.00Positive
100DMA286.48Positive
200DMA271.11Positive

Market Momentum

MACD7.53Negative
RSI66.69Neutral
STOCH73.04Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JLHL, the sentiment is Positive. The current price of 290.45 is above the 20-day moving average (MA) of 266.26, above the 50-day MA of 267.00, and above the 200-day MA of 271.11, indicating a bullish trend. The MACD of 7.53 indicates Negative momentum. The RSI at 66.69 is Neutral, neither overbought nor oversold. The STOCH value of 73.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JLHL.

Jupiter Life Line Hospitals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:JLHL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:YATHARTHIN:YATHARTH80OutperformINR 103.06B54.07―0.05%50.40%24.94%
IN:INDRAMEDCOIN:INDRAMEDCO77OutperformINR 32.42B16.85―1.13%10.72%9.95%
IN:ARTEMISMEDIN:ARTEMISMED73OutperformINR 51.79B44.05―0.14%14.77%8.40%
IN:HCGIN:HCG69NeutralINR 84.79B789.17――12.81%-71.02%
IN:JLHLIN:JLHL66NeutralINR 95.22B51.04―0.07%16.71%-6.09%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:SHALBYIN:SHALBY34UnderperformINR 13.18B33.92――7.27%774.36%

* General Sector Average

Performance Comparison

-25%0%25%50%IN:JLHLIN:ARTEMISMEDIN:HCGIN:INDRAMEDCOIN:SHALBYIN:YATHARTHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:JLHL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:JLHLJupiter Life Line Hospitals Ltd.290.45-0.43-0.15%
IN:ARTEMISMEDArtemis Medicare Services Ltd.327.1539.8313.86%
IN:HCGHealthCare Global Enterprises Ltd.567.90-174.61-23.52%
IN:INDRAMEDCOIndraprastha Medical Corporation Limited353.65-172.94-32.84%
IN:SHALBYShalby Ltd.122.05-99.40-44.89%
IN:YATHARTHYatharth Hospital and Trauma Care Services Limited1069.60301.9539.34%

Jupiter Life Line Hospitals Ltd. Corporate Events

Jupiter Life Line Hospitals Publishes Unaudited Half-Year Financial Results

Oct 25, 2026

Jupiter Life Line Hospitals Ltd. has announced that its Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 at a meeting held on October 23, 2026. In line with...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 26, 2026